Table of Contents Author Guidelines Submit a Manuscript
Analytical Cellular Pathology
Volume 2017, Article ID 1350618, 5 pages
https://doi.org/10.1155/2017/1350618
Clinical Study

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis

Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine and Guangdong Provincial Hospital of Chinese Medicine, Da De Lu No. 111, Guangzhou, Guangdong 510120, China

Correspondence should be addressed to Shi-hong Yang; moc.qq@779555144

Received 15 April 2017; Accepted 24 August 2017; Published 19 September 2017

Academic Editor: Mario D. Cordero

Copyright © 2017 Wei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Fan, K. Strasser-Weippl, J. J. Li et al., “Breast cancer in China,” Lancet Oncology, vol. 15, no. 7, pp. e279–e289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Demonty, C. Bernard-Marry, F. Puglisi, I. Mancini, and M. Piccart, “Progress and new standards of care in the management of HER-2 positive breast cancer,” European Journal of Cancer, vol. 43, pp. 497–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Slamon, W. A. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 7007–7712, 1989. View at Publisher · View at Google Scholar
  4. E. A. Perez, E. H. Romond, V. J. Suman et al., “Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTGN9831,” Clinical Oncology, vol. 32, no. 33, pp. 3744–3752, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. S. V. Liu, L. Melstrom, K. Yao, C. A. Russell, and S. F. Sener, “Neoadjuvant therapy for breast cancer,” Journal of Surgical Oncology, vol. 101, no. 4, pp. 283–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. I. Kim, J. Sohn, J. S. Koo, S. H. Park, H. S. Park, and B. W. Park, “Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer,” Oncology, vol. 79, no. 5-6, pp. 324–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, “Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18,” Journal of the National Cancer Institute. Monographs, vol. 30, pp. 96–102, 2001. View at Publisher · View at Google Scholar
  8. A. U. Buzdr, N. K. Ibrahim, D. Fancis et al., “Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumb, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3676–3685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trail with a parallel HER2-negative cohort,” The Lancet Oncology, vol. 15, no. 6, pp. 640–647, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Untch, P. A. Fasching, G. E. Konecny et al., “Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 29, no. 25, pp. 3351–3357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Untch, S. Loibl, J. Bischoff et al., “Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial,” Lancet Oncology, vol. 13, no. 2, pp. 135–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Peintinger, A. U. Buzdar, H. M. Kuerer et al., “Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab,” Annals of Oncology, vol. 19, no. 12, pp. 2020–2025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Guarneri, K. Broglio, S. W. Kau et al., “Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors,” Journal of Clinical Oncology, vol. 24, pp. 1037–1044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Gianni, J. Baselga, W. Eiermann et al., “Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy,” Clinical Cancer Research, vol. 11, pp. 8715–8721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Kaufmann, C. E. Dauphine, M. P. Vargas et al., “Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery,” The American Surgeon, vol. 72, pp. 935–938, 2006. View at Google Scholar
  16. M. Fernandez-Sanchez, A. Gamboa-Dominguez, N. Uribe et al., “Clinical and pathological predictors of response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer,” Medical Oncology, vol. 23, pp. 171–183, 2006. View at Publisher · View at Google Scholar · View at Scopus